An open label, randomized, phase I/II study of DMXAA in combination with carboplatin and paclitaxel in patients with locally advanced and metastatic non-small cell lung cancer

Trial Profile

An open label, randomized, phase I/II study of DMXAA in combination with carboplatin and paclitaxel in patients with locally advanced and metastatic non-small cell lung cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2015

At a glance

  • Drugs Vadimezan (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Antisoma
  • Most Recent Events

    • 09 Dec 2009 Actual patient number changed from 78 to 105 as reported by ClinicalTrials.gov.
    • 16 Dec 2008 Results published in the British Journal of Cancer.
    • 10 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top